BioPharma Resources

Drug Trial Radar · NCT07517042

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Achieving Sustained Weight Control Via Exercise, Nutrition & Drugs (Mazdutide) (ASCEND- 1 Trial)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Jun 10, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.

Conditions

  • Obesity
  • Weight Control

Interventions

  • MazdutideDrug

    Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.

  • Intensive Lifestyle InterventionBehavioral

    Participants receive a structured intensive lifestyle intervention including individualized dietary counseling, physical activity guidance, and behavioral modification support for 52 weeks during the weight maintenance period.

  • Mazdutide PlaceboDrug

    Mazdutide placebo is administered subcutaneously once weekly for 52 weeks during the weight maintenance period.

  • Usual Lifestyle CounselingBehavioral

    Participants receive general health education and non-intensive lifestyle advice on healthy eating, physical activity, and weight management for 52 weeks during the weight maintenance period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change of body weightTime frame: From randomization to Week 52

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital (Xiamen), Fudan University

    Xiamen, Fujia, China · Recruiting

  • Fujian Provincial Hospital, Affiliated to Fuzhou University

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • The Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University

    Suzhou, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Huadong Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tenth People's Hospital, School of Medicine, Tongji University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tongren Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Provincial People's Hospital

    Taiyuan, Shanxi, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Recruiting

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China · Recruiting

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.